Crossmark

Clinical validation of peripheral blood mononuclear cell DNA methylation markers for accurate early detection of hepatocellular carcinoma in Asian patients

Crossref DOI link: https://doi.org/10.1038/s43856-024-00652-2

Published Online: 2024-10-30

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Cheishvili, David https://orcid.org/0000-0001-9136-8967
Wong, Chifat

Karim, Mohammad Mahbubul https://orcid.org/0000-0003-4882-1775
Golam Kibria, Mohammad https://orcid.org/0000-0002-7821-2455
Jahan, Nusrat https://orcid.org/0000-0001-8700-2209
Chandra Das, Pappu https://orcid.org/0000-0002-6094-0999
Khair Yousuf, Abul

Islam, Atikul

Chandra Das, Dulal

Noor-E-Alam, Sheikh Mohammad

Alam, Sarwar

Rahman, Mustafizur

Khan, Wasif A. https://orcid.org/0000-0002-7650-8068
Al-Mahtab, Mamun https://orcid.org/0000-0003-3728-3879
Szyf, Moshe https://orcid.org/0000-0003-3881-8214
License Information

Text and Data Mining valid from 2024-10-30

Version of Record valid from 2024-10-30
More Information

Article History

Received: 7 January 2024

Accepted: 22 October 2024

First Online: 30 October 2024

Competing interests

: The authors declare the following competing interests: D.C. and C.W. are inventors on a patent application (PCT/IB2019/055855) titled “Methods for predicting or detecting hepatocellular carcinoma”, which includes the tests disclosed in the paper. M.S. is a shareholder in HKG Epitherapeutics Ltd. All other authors declare no competing interests.

Document is current

Any future updates will be listed below